Resolution of subretinal fluid in intractable central serous chorioretinopathy with high-dose intravitreal aflibercept

Abstract

Purpose: To report an unusual case of a patient with intractable central serous chorioretinopathy with a dramatic treatment response to high-dose intravitreal aflibercept. Methods: Retrospective case report. Results: A 40-year-old female patient presented with decreased vision after use of intranasal fluticasone and recent life stressors and was diagnosed with central serous chorioretinopathy. Over a three-year period, she underwent numerous therapies, including seven sessions of photodynamic therapy, intravitreal bevacizumab, standard-dose intravitreal aflibercept, intravitreal faricimab, oral eplerenone, oral acetazolamide, and topical ketorolac, with minimal to no treatment response. After a single treatment with high-dose intravitreal aflibercept, 8 mg, she achieved resolution of subretinal fluid. Conclusion: High-dose intravitreal aflibercept may have a role in management of treatment-resistant central serous chorioretinopathy; further studies are needed.

Keywords

• Central serous chorioretinopathy
• Eylea® HD
• VEGF
• CSCR